Literature DB >> 9042788

Cardiopulmonary pathology in patients with sleep apnea/obesity hypoventilation syndrome.

Q Ahmed1, M Chung-Park, J F Tomashefski.   

Abstract

We reviewed clinical data, autopsy reports, and microscopic slides on 10 patients with sleep apnea/obesity hypoventilation syndrome (SA/OHS) to define the cardiopulmonary pathological features and establish clinicopathologic correlations. Ten obese (>136 kg) patients without SA/OHS were studied as controls. Patients with SA/OHS exhibited biventricular cardiac failure and pulmonary hypertension with a higher prevalence of moderate/severe pulmonary hemosiderosis (8 v 0 patients), alveolar hemorrhage (7 v 4 patients), capillary proliferation (4 v 0 patients), iron encrustation of elastica (1 v 0 patients) and medial hypertrophy of muscular pulmonary arteries (11.9 +/- 2.4 v 9.7 +/- 1.6%) (P < .05). In two patients capillary proliferation resembled capillary hemangiomatosis. Mean right ventricular thickness was higher in the SA/OHS group (0.71 +/- 0.17 v 0.42 +/- 0.1 cm) (P < .01). Four patients with SA/OHS and three controls had moderate/severe myocardial fibrosis. Biventricular cardiac failure caused death in seven patients with SA/OHS. Hypoxia is probably the most important cause of pulmonary hypertension, arterial muscularization, and right ventricular hypertrophy in SA/ OHS. Left ventricular failure in some SA/OHS patients may be the result of hypertensive cardiac disease. In others, the etiology of left ventricular failure was not determined morphologically, suggesting functional abnormalities related to obesity and/or apneic episodes.

Entities:  

Mesh:

Year:  1997        PMID: 9042788     DOI: 10.1016/s0046-8177(97)90122-2

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  14 in total

1.  Strain/strain rate imaging of impaired left atrial function in patients with metabolic syndrome.

Authors:  Ning-Ning Fang; Dong-Xin Sui; Jin-Gui Yu; Hui-Ping Gong; Ming Zhong; Yun Zhang; Wei Zhang
Journal:  Hypertens Res       Date:  2015-07-16       Impact factor: 3.872

2.  Pulmonary arterial hypertension in patients with sleep apnoea syndrome.

Authors:  E Bady; A Achkar; S Pascal; E Orvoen-Frija; J P Laaban
Journal:  Thorax       Date:  2000-11       Impact factor: 9.139

Review 3.  Pulmonary hypertension associated with lung diseases and hypoxemia.

Authors:  Michael J Cuttica
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

Review 4.  Obesity and insulin resistance: effects on cardiac structure, function, and substrate metabolism.

Authors:  Linda R Peterson
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

5.  Reduced sensitivity of the ferroportin Q248H mutant to physiological concentrations of hepcidin.

Authors:  Sergei Nekhai; Min Xu; Altreisha Foster; Ishmael Kasvosve; Sharmin Diaz; Roberto F Machado; Oswaldo L Castro; Gregory J Kato; James G Taylor; Victor R Gordeuk
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

6.  Obesity hypoventilation syndrome.

Authors:  Laila Al Dabal; Ahmed S Bahammam
Journal:  Ann Thorac Med       Date:  2009-04       Impact factor: 2.219

7.  Three subsequent infanticides covered up as SIDS.

Authors:  M Bohnert; M Grosse Perdekamp; S Pollak
Journal:  Int J Legal Med       Date:  2004-05-14       Impact factor: 2.686

Review 8.  Pulmonary capillary haemangiomatosis in children and adolescents: report of a new case and a review of the literature.

Authors:  Katalin Bartyik; Olga Bede; Laszlo Tiszlavicz; Beata Onozo; Istvan Virag; Sandor Turi
Journal:  Eur J Pediatr       Date:  2004-12       Impact factor: 3.183

Review 9.  Cardiac remodeling in obesity.

Authors:  E Dale Abel; Sheldon E Litwin; Gary Sweeney
Journal:  Physiol Rev       Date:  2008-04       Impact factor: 37.312

10.  Cardiac changes noted within 4 years of transplant in postmortem evaluation of a patient with untreated obstructive sleep apnea.

Authors:  Nancy F Fishback; George R Wettach
Journal:  Sleep Breath       Date:  2004-06       Impact factor: 2.816

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.